Leidos teams with CareDx to transform the Organ Procurement and Transplantation Network

(RESTON, Va.) January 24, 2025 - Leidos (NYSE: LDOS) today announced its collaboration with CareDx - The Transplant Company^™ (Nasdaq: CDNA) to help drive one of the most significant modernizations of the Organ Procurement and Transplantation Network (OPTN) in nearly four decades. This reform seeks to make the organ transplantation process more transparent, inclusive and effective for patients across the nation.

As part of this multi-layered initiative, Leidos and CareDx, a leader in innovative transplant solutions, will combine their expertise to design and implement innovations to help enhance every stage of the pre- and post-transplant journey. The companies will focus on advancing technologies, generating actionable insights, and streamlining operations with the goal of improving performance, governance and efficiency in organ transplantation.

"We are proud to team with CareDx, whose expertise in the organ transplant ecosystem complements Leidos' strengths in technology, health systems and large-scale electronic health record implementations," said Liz Porter, Leidos Health & Civil Sector president. "Together, we are uniquely positioned to create transformative solutions that are designed to improve the lives of patients and their families, while supporting the critical reforms needed to modernize the OPTN."

CareDx President and CEO, John W. Hanna, added: "Working with Leidos allows us to combine our transplant expertise and innovative digital solutions to address the most pressing challenges in organ transplantation. Together, we are committed to expanding access to transplants, improving patient outcomes and supporting the continued success of key OPTN functions."

This joint effort represents a significant step toward building a more resilient and effective organ transplant system that benefits patients, families and healthcare providers alike.

Leidos, in collaboration with CareDx, was awarded a multiple-award, indefinite delivery/indefinite quantity contract with a ceiling of $235 million by the U.S. Department of Health and Human Services, Health Resources and Services Administration. Under this contract, Leidos will have the opportunity to compete with other vendors to modernize key pieces of the organ transplant system to better serve the more than 100,000 individuals on the national organ transplant waitlist.

About Leidos

Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 48,000 global employees, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. For more information, visit www.leidos.com.

About CareDx - The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.caredx.com.

Certain statements in this announcement constitute "forward-looking statements" within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management's current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the "Risk Factors" set forth in Leidos' Annual Report on Form 10-K for the fiscal year ended December 29, 2023, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.